17th June 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Innova Captab expected to file for 900-crore IPO soon

Drugmaker Innova Captab will soon file a draft red herring prospectus (DRHP) with market regulator Sebi for a 900-crore initial public offering (IPO). Mumbai-based firm specialises in generic formulation contract development and manufacturing.

Roche faces a setback in Alzheimer's treatment

Govt. recently introduced product linked incentive (PLI) plan for the pharma sector in response to the pandemic’s significant disruptions across the industry and to enhance the capacity of local manufacturing of vital pharmaceuticals.

GSK plans to release the first RSV vaccine following positive results

GSK said its vaccine targeting a respiratory virus that causes hundreds of thousands of hospitalizations in older adults each year produced positive results in a trial, giving the drugmaker a boost after falling behind in the race to develop a Covid shot.

Tivic Health receives its second Global Health & Pharma Award

Tivic Health Systems has announced that ClearUP Sinus Pain Relief has won the Global Health & Pharma 2022 award for Most Innovative Sinus Relief Solution for the second year in a row.

Humanigen and PCI Pharma Services form Partnership for Lenzilumab

Humanigen, a biopharmaceutical company focused on preventing and treating cytokine storm, has signed an agreement with PCI Pharma Services, a global CDMO, to provide importation, release, & commercialization services for lenzilumab in the UK.

PerkinElmer & Novartis teamed up to address Sickle Cell Disease's unmet needs in Sub-Saharan Africa

PerkinElmer and the Novartis Africa Sickle Cell Disease initiative want to increase their advocacy efforts to educate patients, caregivers, and communities about the need of newborn screening and early treatment with hydroxyurea (HU) and other SCD medications.

Rhythm Pharma signed financing agreement with Healthcare Royalty for upto $100 million

RYTM will receive an initial payment of $37.5 million from HealthCare Royalty as a result of the FDA’s approval of its Imcivree medicine for the treatment of obesity in Bardet-Biedl syndrome patients.